Sangamo Historical Balance Sheet
SGMO Stock | USD 2.63 0.13 5.20% |
Trend analysis of Sangamo Therapeutics balance sheet accounts such as Liabilities And Stockholders Equity of 218.1 M, Other Stockholder Equity of 1.6 B, Total Liabilities of 73.5 M or Short Long Term Debt Total of 30 M provides information on Sangamo Therapeutics' total assets, liabilities, and equity, which is the actual value of Sangamo Therapeutics to its prevalent stockholders. By breaking down trends over time using Sangamo Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Sangamo Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Sangamo Therapeutics is a good buy for the upcoming year.
Sangamo Therapeutics Inventory |
|
Sangamo |
About Sangamo Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Sangamo Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Sangamo Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Sangamo Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Sangamo currently owns. An asset can also be divided into two categories, current and non-current.
Sangamo Therapeutics Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Sangamo Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Sangamo Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most accounts from Sangamo Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Sangamo Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.At this time, Sangamo Therapeutics' Non Currrent Assets Other are very stable compared to the past year. As of the 26th of December 2024, Non Current Liabilities Total is likely to grow to about 57.7 M, though Retained Earnings are likely to grow to (1.3 B).
2021 | 2022 | 2023 | 2024 (projected) | |
Total Stockholder Equity | 375.3M | 295.0M | 82.9M | 144.6M |
Total Assets | 721.9M | 562.5M | 165.3M | 218.1M |
Sangamo Therapeutics balance sheet Correlations
Click cells to compare fundamentals
Sangamo Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sangamo Therapeutics balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 637.5M | 938.6M | 721.9M | 562.5M | 165.3M | 218.1M | |
Total Stockholder Equity | 432.7M | 497.4M | 375.3M | 295.0M | 82.9M | 144.6M | |
Retained Earnings | (657.0M) | (778.0M) | (956.3M) | (1.1B) | (1.4B) | (1.3B) | |
Other Assets | 10.6M | 15.1M | 16.8M | 18.5M | 1.0 | 0.95 | |
Common Stock Shares Outstanding | 112.1M | 134.4M | 144.6M | 154.3M | 174.4M | 183.2M | |
Liabilities And Stockholders Equity | 637.5M | 938.6M | 721.9M | 562.5M | 165.3M | 218.1M | |
Other Stockholder Equity | 1.1B | 1.3B | 1.3B | 1.5B | 1.5B | 1.6B | |
Total Liab | 204.8M | 441.2M | 346.6M | 267.6M | 82.4M | 73.5M | |
Short Long Term Debt Total | 44.4M | 42.1M | 48.1M | 43.1M | 38.1M | 30.0M | |
Other Current Liab | 21.3M | 127.3M | 28.4M | 33.4M | 27.9M | 14.0M | |
Total Current Liabilities | 69.9M | 143.5M | 127.9M | 111.7M | 47.7M | 34.0M | |
Property Plant And Equipment Net | 107.2M | 112.4M | 124.7M | 125.5M | 52.9M | 29.2M | |
Accounts Payable | 6.7M | 12.6M | 9.8M | 22.4M | 15.3M | 16.0M | |
Cash | 80.4M | 131.3M | 178.9M | 100.4M | 45.2M | 45.0M | |
Non Current Assets Total | 232.0M | 278.9M | 323.2M | 262.2M | 71.0M | 68.1M | |
Non Currrent Assets Other | 4.0M | 7.9M | 10.2M | 12.3M | 18.1M | 19.0M | |
Cash And Short Term Investments | 385.0M | 692.0M | 464.7M | 277.6M | 81.0M | 77.0M | |
Net Receivables | 37.6M | 6.3M | 6.4M | 4.5M | 1.3M | 1.3M | |
Common Stock Total Equity | 1.2M | 1.4M | 1.5M | 1.7M | 1.5M | 1.4M | |
Short Term Investments | 282.0M | 510.1M | 197.7M | 177.2M | 35.8M | 34.0M | |
Non Current Liabilities Total | 134.9M | 297.6M | 218.7M | 155.8M | 34.7M | 57.7M | |
Property Plant And Equipment Gross | 107.2M | 112.4M | 149.7M | 162.1M | 103.9M | 109.1M | |
Total Current Assets | 405.5M | 659.7M | 398.8M | 300.3M | 94.3M | 175.7M | |
Accumulated Other Comprehensive Income | (2.4M) | 5.4M | (4.0M) | (8.4M) | (4.6M) | (4.4M) | |
Common Stock | 1.2M | 1.4M | 1.5M | 1.7M | 1.8M | 1.7M | |
Net Debt | (36.0M) | (89.2M) | (130.8M) | (57.3M) | (7.1M) | (7.5M) | |
Other Current Assets | 5.4M | 24.0M | 31.7M | 36.4M | 12M | 12.6M | |
Property Plant Equipment | 29.9M | 41.3M | 51.5M | 63.5M | 73.1M | 76.7M | |
Current Deferred Revenue | 38.7M | 96.6M | 85.7M | 51.8M | 59.5M | 62.5M | |
Intangible Assets | 53.2M | 58.1M | 53.8M | 50.7M | 58.3M | 61.3M | |
Other Liab | 93.7M | 259.2M | 174.6M | 116.9M | 134.4M | 141.1M | |
Net Tangible Assets | 340.1M | 397.3M | 281.9M | 206.7M | 237.7M | 227.0M | |
Retained Earnings Total Equity | (657.0M) | (778.0M) | (956.3M) | (1.1B) | (1.0B) | (982.0M) | |
Capital Surpluse | 1.1B | 1.3B | 1.3B | 1.5B | 1.7B | 873.1M | |
Inventory | (22.5M) | (50.5M) | (88.2M) | 1.0 | 0.9 | 0.95 | |
Deferred Long Term Liab | 6.6M | 7.2M | 6.6M | 6.3M | 7.2M | 9.3M |
Pair Trading with Sangamo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sangamo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sangamo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Sangamo Stock
0.77 | ME | 23Andme Holding | PairCorr |
0.77 | DOMH | Dominari Holdings | PairCorr |
0.74 | VINC | Vincerx Pharma | PairCorr |
0.68 | VALN | Valneva SE ADR | PairCorr |
0.68 | DTIL | Precision BioSciences | PairCorr |
The ability to find closely correlated positions to Sangamo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sangamo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sangamo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sangamo Therapeutics to buy it.
The correlation of Sangamo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sangamo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sangamo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sangamo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.24) | Revenue Per Share 0.066 | Quarterly Revenue Growth (0.95) | Return On Assets (0.58) | Return On Equity (1.94) |
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.